{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:07Z","timestamp":1791499627836,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical outcomes in aNSCLC in the United Kingdom.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Electronic prescribing records of treatment-naive patients starting first-line (1\u2009L) treatment for aNSCLC between June 2016 and March 2018 (follow-up until December 2018) in the United Kingdom were assessed retrospectively. Patient characteristics and treatment patterns were analyzed descriptively. Outcomes assessed included overall survival (OS), time to treatment discontinuation, time to next treatment, and real-world tumor response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In all, 1003 patients were evaluated (median age, 68\u2009years [range, 28\u201393\u2009years]; 53.9% male). Use of 1\u2009L IO monotherapy (0\u201325.9%) and targeted therapy (11.8\u201315.9%) increased during the study period, but chemotherapy remained the most common 1\u2009L treatment at all time points (88.2\u201358.2%). Median OS was 9.5\u2009months (95% CI, 8.8\u201310.7\u2009months) for all patients, 8.1\u2009months (95% CI, 7.4\u20138.9\u2009months) with chemotherapy, 14.0\u2009months (95% CI, 10.7\u201320.6\u2009months) with IO monotherapy, and 20.2\u2009months (95% CI, 16.0\u201330.5\u2009months) with targeted therapy. In the 28.6% of patients who received second-line treatment, IO monotherapy was the most common drug class (used in 51.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although use of 1\u2009L IO monotherapy for aNSCLC increased in the United Kingdom during the study period, most patients received 1\u2009L chemotherapy. An OS benefit for first-line IO monotherapy vs chemotherapy was observed but was numerically smaller than that reported in clinical trials. Targeted therapy was associated with the longest OS, highlighting the need for improved treatment options for tumors lacking targetable mutations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08096-w","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T12:03:55Z","timestamp":1620389035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2311-070X","authenticated-orcid":false,"given":"Jason","family":"Lester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Escriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Mansy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Conibear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Nelless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaneet","family":"Nayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amerah","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"8096_CR1","unstructured":"Royal College of Physicians. National Lung Cancer Audit annual report 2016 (for the audit period 2015). Available at: https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/nlca-annual-report-2016. Accessed 4 May\u00a02020."},{"key":"8096_CR2","unstructured":"Cancer Research UK. Types of lung cancer. Available at: https:\/\/www.cancerresearchuk.org\/about-cancer\/lung-cancer\/stages-types-grades\/types. Accessed\u00a0 4 May\u00a0\u00a02020."},{"issue":"suppl_4","key":"8096_CR3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1\u2013iv21.","journal-title":"Ann Oncol"},{"key":"8096_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2016.11.020","volume":"103","author":"F Kaniski","year":"2017","unstructured":"Kaniski F, Enewold L, Thomas A, Malik S, Stevens JL, Harlan LC. Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010. Lung Cancer. 2017;103:66\u201374. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.020.","journal-title":"Lung Cancer"},{"issue":"2","key":"8096_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lungcan.2008.08.011","volume":"64","author":"HA Azim Jr","year":"2009","unstructured":"Azim HA Jr, Elattar I, Loberiza FR Jr, Azim H, Mok T, Ganti AK. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer. 2009;64(2):194\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2008.08.011.","journal-title":"Lung Cancer"},{"key":"8096_CR6","doi-asserted-by":"crossref","unstructured":"Azim HA, Ganti AK, Elattar I, Azim H, Loberiza FR. Triplets vs. doublets in the management of advanced non-small cell lung cancer (NSCLC) using third generation chemotherapeutic agents: a meta-analysis. J Clin Oncol. 2007;25(18_suppl):Abstract 7580.","DOI":"10.1200\/jco.2007.25.18_suppl.7580"},{"key":"8096_CR7","doi-asserted-by":"publisher","unstructured":"Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, et al. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for Medicare patients 65 years and older with advanced non-small-cell lung cancer: a retrospective study. Clin Lung Cancer. 2018;19(5):e629\u201345. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.017.","DOI":"10.1016\/j.cllc.2018.04.017"},{"key":"8096_CR8","unstructured":"Cancer Research UK. Lung cancer statistics. Available at: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Two. Accessed 4 May\u00a02020."},{"issue":"Suppl 1","key":"8096_CR9","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.21037\/jtd.2019.01.46","volume":"11","author":"EH Bernicker","year":"2019","unstructured":"Bernicker EH, Allen TC, Cagle PT. Update on emerging biomarkers in lung cancer. J Thorac Dis. 2019;11(Suppl 1):S81\u20138. https:\/\/doi.org\/10.21037\/jtd.2019.01.46.","journal-title":"J Thorac Dis"},{"issue":"19","key":"8096_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"10183","key":"8096_CR11","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7.","journal-title":"Lancet."},{"issue":"suppl 5","key":"8096_CR12","first-page":"Abstract LBA78","volume":"30","author":"D Spigel","year":"2019","unstructured":"Spigel D, De Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios CH, et al. IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1\u2013selected NSCLC. Ann Oncol. 2019;30(suppl 5):Abstract LBA78.","journal-title":"Ann Oncol"},{"key":"8096_CR13","unstructured":"United Kindom Early Access to Medicines Schemes [Available at: https:\/\/www.gov.uk\/government\/publications\/early-access-to-medicines-scheme-expired-scientific-opinions\/expired-early-access-to-medicines-scheme-scientific-opinions]."},{"key":"8096_CR14","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy: technology appraisal guidance [TA428]. Available at: www.nice.org.uk\/guidance\/ta428. Accessed May 4\u00a02020."},{"key":"8096_CR15","unstructured":"National Institute for Health and Care Excellence (NICE). Nivolumab for previously treated squamous non-small-cell lung cancer: technology Appraisal Guidance [TA483]. Available at: www.nice.org.uk\/guidance\/ta483. Accessed 4 May\u00a02020.\u00a0"},{"key":"8096_CR16","unstructured":"National Institute for Health and Care Excellence (NICE). Atezolizumab for treating locally advanced or metastatic non-small-cell advanced or metastatic non-small-cell lung cancer after chemotherapy: technology appraisal guidance [TA520]. Avalable at: www.nice.org.uk\/guidance\/ta520. Accessed 4 May\u00a02020."},{"key":"8096_CR17","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: technology appraisal guidance [TA531]. Available at: www.nice.org.uk\/guidance\/ta531. Accessed 4 May\u00a02020."},{"key":"8096_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer: technology appraisal guidance [TA557]. Available at: www.nice.org.uk\/guidance\/ta557. Accessed May 4, 2020."},{"key":"8096_CR19","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer: technology appraisal guidance [TA600]. Available at: www.nice.org.uk\/guidance\/ta600. Accessed 4 May\u00a02020."},{"key":"8096_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer: technology appraisal guidance [TA584]. Available at: www.nice.org.uk\/guidance\/ta584. Accessed 4 May\u00a02020."},{"key":"8096_CR21","doi-asserted-by":"publisher","unstructured":"Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326\u201335. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00186.x.","DOI":"10.1111\/j.1524-4733.2007.00186.x"},{"issue":"4","key":"8096_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175679","volume":"12","author":"J Davies","year":"2017","unstructured":"Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies. PLoS One. 2017;12(4):e0175679. https:\/\/doi.org\/10.1371\/journal.pone.0175679.","journal-title":"PLoS One"},{"key":"8096_CR23","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0169-5002(18)30118-1","volume":"115","author":"M Snee","year":"2018","unstructured":"Snee M, Cheeseman S, Thompson M, Godden P, Sopwith W, Chaib C, et al. Clinical characteristics and overall survival of patients diagnosed with non-small cell lung cancer (NSCLC) between 2006 and 2017 in routine clinical practice: a retrospective analysis of a UK hospital database. Lung Cancer. 2018;115:S38. https:\/\/doi.org\/10.1016\/S0169-5002(18)30118-1.","journal-title":"Lung Cancer"},{"issue":"5","key":"8096_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30(5):830\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz060.","journal-title":"Ann Oncol"},{"key":"8096_CR25","doi-asserted-by":"publisher","first-page":"x22","DOI":"10.1093\/annonc\/mdy486.014","volume":"29","author":"M Wang","year":"2018","unstructured":"Wang M, Dhokia P, Menon S, Martindale B. First-line systemic real-world treatment of patients with advanced\/metastatic NSCLC in the UK. Ann Oncol. 2018;29:x22. https:\/\/doi.org\/10.1093\/annonc\/mdy486.014.","journal-title":"Ann Oncol"},{"key":"8096_CR26","doi-asserted-by":"crossref","unstructured":"Snee M, Cheeseman S, Thompson M, Lacoin L, Sopwith W, Godden P, et al. Treatment patterns in patients with stage IIIB-IV NSCLC in clinical practice: retrospective analysis of a UK Trust database. Thorax. 2018;73(Suppl 4):A145\u20136 (abstract P182).","DOI":"10.1136\/thorax-2018-212555.240"},{"issue":"21","key":"8096_CR27","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med"},{"issue":"10027","key":"8096_CR28","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet."},{"issue":"3","key":"8096_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00432-020-03414-4","volume":"147","author":"E Nadler","year":"2021","unstructured":"Nadler E, Arondekar B, Aguilar KM, Zhou J, Chang J, Zhang X, et al. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. J Cancer Res Clin Oncol. 2021;147(3):671\u201390. https:\/\/doi.org\/10.1007\/s00432-020-03414-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"8096_CR30","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1016\/j.jtho.2019.08.483","volume":"14","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non\u2013small-cell lung cancer. J Thorac Oncol. 2019;14(10):S243 (abstract OA214.201).","journal-title":"J Thorac Oncol"},{"key":"8096_CR31","doi-asserted-by":"crossref","unstructured":"Snee M, Cheeseman S, Thompson M, Riaz M, Lacoin L, Sopwith W, et al. Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: a real-oncology database analysis from the I-O Optimise initiative. Ann Oncol. 2019;30:ii14\u20135.","DOI":"10.1093\/annonc\/mdz070.002"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08096-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08096-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08096-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T12:07:27Z","timestamp":1620389247000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08096-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8096"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08096-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"8 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was gained through Health Research Authority from the London - Bromley Research Ethics Committee. All data was pseudonymised at source, no patient identifiable data were collected and patient consent was therefore not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approve of submission of the manuscript and give their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JL has received honoraria and sponsorship from and participated in advisory boards for Roche, AstraZeneca, Pfizer, Boehringer Ingelheim, MSD, Bristol-Myers Squibb, and Lilly. CE has received travel grants from MSD, Roche, AstraZeneca, and Boehringer Ingelheim; consultancy fees from MSD, AstraZeneca, and Boehringer Ingelheim; and lecturer fees from Pfizer, AstraZeneca, and Roche. EH has participated in advisory board work for Roche, Tesaro, and GSK. TM has associations with MSD, Bristol-Myers Squibb, AstraZeneca, Roche, Boehringer Ingelheim, PharmaMar, and Tesaro. AC received an educational grant from Servier. SC has received speaker\u2019s fees from Bristol-Myers Squibb. CP has received sponsorship to conferences from Boehringer Ingelheim and Roche and honoraria for talks and session chairing from Boehringer Ingelheim and Bristol-Myers Squibb. X Zhuo was an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, when the analysis was conducted and is now an employee of Bristol-Myers Squibb. AD was an employee of Merck Serono Ltd., Feltham, United Kingdom, an affiliate of Merck KGaA, Darmstadt, Germany, when the analysis was conducted and is now an employee of Novartis. AA, PM, X Zhang, and VP are current employees of Merck KGaA, Darmstadt, Germany. SK, JB, JC, LN, and VN have no relationships to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"515"}}